One in five patients referred for vascular access surgery experience an unsustainable treatment burden, with poor health ...

Xeltis’ vascular access graft, aXess, recently demonstrated strong efficacy in an EU pivotal trial in patients with end-stage ...

The EIB financing consists of €10 million upfront, with the option to access an additional €27.5 million as Xeltis progresses ...

Thrombotic risk with PICCs matched that of totally implantable venous access devices, showing comparable long-term safety.

Xeltis announced today that it secured €47.5 million ($55.1 million) in financing to support its vascular access device.

Please provide your email address to receive an email when new articles are posted on . Of the nearly 783,000 Americans with kidney failure, approximately 500,000 of these patients require ...

Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces that it has secured nearly €50m of new financing, consisting ...

This field refers to the type of vascular access used to dialyze the patient during the last treatment that the user’s facility provided that patient during the reporting month. This field allows the ...

The global vascular access device market grew from USD 5.11 billion in 2024 to USD 5.48 billion in 2025. Forecasts indicate continued expansion at a CAGR of 7.90%, reaching USD 9.

The global Pediatric Vascular Access Market , valued at US$511.3 million in 2023, stood at US$543.0 million in 2024 and is ...

Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces that it has secured nearly EUR50m of new financing, ...